Table 3.

The prevalence of antimicrobial drug resistance among Klebsiella pneumoniae isolates according to individual studies

References	N	AMK	ATM	CAZ	CIP	COL	CTX	FEP	GEN	IPM	LVX	MEM	SXT
Liu et al. [30]	106	33	49	106	49	0	–	92	33	106	49	106	16
Tian et al. [39]	170	99	161	170	107	5	170	–	105	163	105	162	139
Zhao et al. [40]	63	48	61	62	59	–	–	58	50	62	56	63	–
Meng et al. [41]	142	45	89	78	67	–	–	81	69	–	60	–	42
Kim et al. [42]	579	–	139	–	141	–	–	–	–	–	–	–	131
Xu et al. [43]	30	16	–	29	26	–	28	24	–	–	23	–	–
Guo et al. [44]	8203	2568	4323	4077	4184	–	6005	2887	4651	468	–	476	5357
Dong et al. [29]	52	3	47	52	8	0	–	51	37	46	4	49	47
Cha et al. [45]	54	–	–	53	51	–	52	34	–	13	–	7	–
Mitra et al. [52]	55	45	50	–	52	–	53	–	52	–	–	29	49
Gautam et al. [53]	304	109	–	159	115	8	157	155	–	103	–	120	–
Mansury et al. [54]	38	6	–	–	–	–	19	–	16	6	–	4	–
Heidary et al. [55]	117	40	75	73	–	5	77	–	51	28	–	28	–
Ma et al. [56]	760	–	–	–	–	–	–	–	–	568	–	519	–
Sum		3012	4994	4859	4859	18	6561	3382	5064	1563	297	1563	5781
Rate (%)		40.8	73.3	75.7	59.8	2.9	79.2	72.6	58	65.6	54.1	62.7	58.2

AMK, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; COL, colistin; CTX, cefotaxime; FEP, cefepime; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; SXT, trimethoprim-sulfamethoxazole